Sugi Predict

Sugi Predict / Compounds / SCHEMBL5166912

SCHEMBL5166912

SCHEMBL5166912

CC(=O)N(c1c(-c2cccc3ccccc23)nc2cc(C)ccn12)C(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.43
▸ GAA P10253 9/20 0.43
▸ SMN1; SMN2 Q16637 7/20 0.41
▸ TP53 P04637 4/20 0.41
▸ THRB P10828 1/20 0.41
▸ CGAS Q8N884 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ PARP1 P09874 1/20 0.37
▸ HTT P42858 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ NPSR1 Q6W5P4 2/20 0.37
▸ TDP1 Q9NUW8 2/20 0.37
▸ MITF O75030 1/20 0.37
▸ POLB P06746 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5168236 0.90 GAA (0.41) MAPTGAASMN1; SMN2TP53THRB
SCHEMBL5167634 0.80 NPC1 (0.42) GAASMN1; SMN2CGASL3MBTL1NPC1
SCHEMBL5168273 0.80 GAA (0.57) MAPTGAASMN1; SMN2TP53CGAS
SCHEMBL5167746 0.78 GAA (0.49) MAPTGAASMN1; SMN2TP53CGAS
SCHEMBL5165510 0.75 MAPT (0.41) MAPTGAASMN1; SMN2TP53CGAS
SCHEMBL5169244 0.74 GAA (0.42) MAPTGAASMN1; SMN2TP53THRB
SCHEMBL6650928 0.73 GAA (0.60) MAPTGAASMN1; SMN2TP53THRB
SCHEMBL5166045 0.72 MAPK13 (0.44) GAANPC1RAB9AALDH1A1KMT2A
SCHEMBL5169251 0.72 GAA (0.40) MAPTGAASMN1; SMN2TP53THRB
SCHEMBL5167216 0.71 HSD17B10 (0.40) NPC1RAB9AALDH1A1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040023972-A1 Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS GRUENENTHAL GMBH (DE) 2004-02-05 — — US claimed
EP-1326613-B2 USE OF SUBSTITUTED IMIDAZO 1,2-A|PYRIDINE-, IMIDAZO ¬1,2-A|PYRIMIDINE AND IMIDAZO ¬1,2-A|PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS GRUENENTHAL GMBH (DE) 2007-04-18 — — EP disclosed
EP-1326613-B1 USE OF SUBSTITUTED IMIDAZO 1,2-A]PYRIDINE-, IMIDAZO [1,2-A]PYRIMIDINE AND IMIDAZO [1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS GRUENENTHAL GMBH (DE) 2004-06-02 — — EP disclosed
US-20040023972-A1 Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS GRUENENTHAL GMBH (DE) 2004-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023972-A1 Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS NOS1, PTGIS, NOS2 MAPT 203/4885GAA 536/4885SMN1; SMN2 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.